Drug Profile

Artemisinin - Oncotelic Therapeutics

Alternative Names: ArtiShield

Latest Information Update: 03 Jun 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Mateon Therapeutics
Developer Oncotelic Therapeutics
Class Antivirals; Small molecules
Mechanism of Action TGF-beta superfamily protein inhibitors; Virus replication inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Suspended COVID 2019 infections

Most Recent Events

03 Jun 2024 Suspended - Preclinical for COVID-2019 infections in USA (Parenteral) prior to December 2023
19 Aug 2020 Mateon Therapeutics and Windlas enters into a co-development agreement for the development and commercialisation of artemisinin
20 Jul 2020 Preclinical trials in COVID-2019 infections in USA (Parenteral), before July 2020

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com